Literature DB >> 23334074

Lamotrigine augmentation in premenstrual dysphoric disorder: a case report.

Gianna Sepede1, Giovanni Martinotti, Francesco Gambi, Rosa Maria Salerno, Massimo Di Giannantonio.   

Abstract

Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome, characterized by depressive, anxious, and somatic symptoms, associated to a significant reduction in social functioning and quality of life. Although selective serotonin reuptake inhibitors (SSRIs) and oral contraceptives show a substantial effectiveness in PMDD, a wide percentage of women affected by PMDD do not respond to those first-line treatments. We present the case of a 42-year-old woman, affected by a disabling form of PMDD, who partially responded to an SSRI treatment and significantly improved after an add-on therapy with lamotrigine. We therefore suggest that lamotrigine may be an efficacious and safe augmentation strategy in severe PMDD cases showing unsatisfactory or partial response to SSRI treatments.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23334074     DOI: 10.1097/WNF.0b013e318279ee1f

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  2 in total

1.  Lamotrigine and GABAA receptor modulators interact with menstrual cycle phase and oral contraceptives to regulate mood in women with bipolar disorder.

Authors:  Thalia K Robakis; Jessie Holtzman; Pascale G Stemmle; Margaret F Reynolds-May; Heather A Kenna; Natalie L Rasgon
Journal:  J Affect Disord       Date:  2014-12-24       Impact factor: 4.839

Review 2.  Comorbid Premenstrual Dysphoric Disorder in Women with Bipolar Disorder: Management Challenges.

Authors:  Gianna Sepede; Marcella Brunetti; Massimo Di Giannantonio
Journal:  Neuropsychiatr Dis Treat       Date:  2020-02-10       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.